Baveno VII is a sequel of the Baveno I-VI Workshops, which were held every 5 years from 1990 to 2015. All the previous Workshops were successful, as proven by more than 3000 citations of the Workshop reports in the medical literature. After Baveno VI, important advances have been made in understanding the
pathophysiology of portal hypertension, as well as in developing new treatments and new strategies for the management of advanced cirrhosis and portal hypertension. For these reasons, we thought that the time had come to organize a seventh Baveno Workshop.
As for the previous editions, the aim of the Baveno VII Workshop is twofold: first, to review and put into perspective the changes in diagnostic and therapeutic strategies that have occurred in the past 5 years in the field of portal hypertension. Second, to continue the effort – which had begun in Baveno I thirty years ago – of producing updated definitions and guidelines aimed at improving the management of patients as well as the quality of our future studies.
The Workshop will begin with a brief introduction, followed by three lectures, the first one on the new concept of risk stratification, the second one on competing risks and stages in cirrhosis, and the third on life style and genetic modifiers of progression of compensated advanced chronic liver disease.
Topics to be covered
The structure of the Workshop is similar to that of the previous ones – there will be 4 sessions: each divided into 2-3 parts.
The first session will concern the evaluation and risk stratification of patients with cirrhosis, focusing on the HVPG as a gold standard and on non-invasive surrogates for the diagnosis of compensated advanced chronic liver disease, clinically significant portal hypertension and varices.
The second session, dedicated to the new clinical scenarios will be divided into three parts. The first one will include four introductory lectures on progression and regression of cirrhosis; the second one will analyze the impact of etiological therapy for cirrhosis, and the third one will deal with the impact of non-etiological novel therapies in cirrhosis.
The third session will deal with the different clinical settings and will also be divided into three parts: the first one will be devoted to the prevention of (first) decompensation, the second one to acute variceal hemorrhage, and the third one to the prevention of further decompensation.
The fourth session will be devoted to vascular liver diseases in cirrhosis, and will consist of two parts: the first one on diagnosis and staging, and the second one to treatment. According to the Baveno tradition, at the end of each session, updated consensus statements on the topic of the session will be presented and discussed by the Panels and the Audience.